Summary
This study is open to adults with small cell lung cancer and other neuroendocrine cancers
that are positive for the tumour marker delta-like 3 (DLL3). The study is in people with
advanced cancer for whom previous treatment was not successful or no standard treatment
exists.
The purpose of this study is to find out the highest dose of BI 764532 and the best
treatment schedule that people can tolerate. BI 764532 is an antibody-like molecule
(DLL3/CD3 bispecific) that may help the immune system fight cancer. In this study, BI
764532 is given to people for the first time. That means no clinical data are available
for BI 764532.
Participants get BI 764532 either weekly or once every 3 weeks. If there is benefit for
the participants and if they can tolerate it, the treatment is given for a maximum of 3
years. During this time, participants visit the study site about 20 times depending on
the response to the treatment. Doctors record any unwanted effects and regularly check
the general health of the participants.